PDUFA VII commitment letter: RWE, rare diseases see renewed attention

Regulatory NewsRegulatory NewsBiologicsChemistry, Manufacturing and Controls (CMC)Clinical TrialsCombination ProductsFDA meeting and communication strategyNorth AmericaPharmaceuticalsProduct LifecycleQuality Assurance and ControlResearch, Design and Development